Literature DB >> 2573417

Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma.

D Fults1, R H Tippets, G A Thomas, Y Nakamura, R White.   

Abstract

Loss of constitutional heterozygosity for specific chromosomal loci, when found consistently in a particular tumor type, suggests that a recessive oncogene important in the genesis of that tumor may be present within the involved chromosomal loci. DNA markers that detect restriction fragment length polymorphisms are powerful tools that have been used to detect loss of chromosomal loci in a growing number of human malignancies. The human brain tumor astrocytoma is usually malignant and virtually incurable. Two types of malignant astrocytomas are recognized histopathologically:anaplastic astrocytoma and glioblastoma multiforme. We carried out a restriction fragment length polymorphism analysis of tumors from 15 patients with anaplastic astrocytoma and 20 patients with glioblastoma using polymorphic DNA markers for loci on chromosome 17. Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40% of cases). Our mapping data revealed a region of loss on chromosome 17p between physical loci p11.2 and pter that was common to both patient groups. Taken together with the previously reported finding of loss of heterozygosity for loci on chromosome 10 in glioblastoma, these results indicate that tumorigenesis in the astrocyte lineage may involve recessive oncogenes on two different chromosomes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573417

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

Review 1.  Molecular genetics of neurological tumours.

Authors:  R Y Chung; B R Seizinger
Journal:  J Med Genet       Date:  1992-06       Impact factor: 6.318

2.  Loss of heterozygosity for DNA polymorphisms mapping to chromosomes 10 and 17 and prognosis in patients with gliomas.

Authors:  C E Jones; M B Davis; J L Darling; J F Geddes; D G Thomas; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

3.  Deletions on the long arm of chromosome 17 in pilocytic astrocytoma.

Authors:  A von Deimling; D N Louis; A G Menon; K von Ammon; I Petersen; D Ellison; O D Wiestler; B R Seizinger
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 4.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

5.  Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.

Authors:  A L Børresen; E Hovig; B Smith-Sørensen; D Malkin; S Lystad; T I Andersen; J M Nesland; K J Isselbacher; S H Friend
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

6.  p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies.

Authors:  E Karamitopoulou; E Perentes; I Diamantis
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

7.  p53 immunoreactivity in oligodendrogliomas.

Authors:  J Pavelić; V Hlavka; M Poljak; N Gale; K Pavelić
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Molecular biology of pediatric gliomas.

Authors:  C Raffel
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

Review 9.  Genetics of cancer predisposition and progression.

Authors:  K Schwechheimer; W K Cavenee
Journal:  Clin Investig       Date:  1993-06

10.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.